Transactions
1
Insider / TEVA PHARMACEUTICAL INDUSTRIES LTD
Zaks Tal Zvi
Director at TEVA PHARMACEUTICAL INDUSTRIES LTD
- Ticker
- TEVA
- First filing on record
- August 10, 2026
- Latest trade on record
- August 5, 2026
- SEC filings
- EDGAR ↗
Zaks Tal Zvi, Director at TEVA PHARMACEUTICAL INDUSTRIES LTD, has disclosed 1 transaction in TEVA since August 10, 2026: 0 purchases (0 open-market buys) and 1 sale, worth about $593 at the reported prices. The latest was filed August 10, 2026, 5 days after the trade; 1 filing was late against the 2-business-day Form 4 deadline.
Open-market buys
0
Sales
1
Avg. disclosure lag
5.0d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)
In the last 12 months Zaks Tal Zvi made no purchases and 1 sale worth $593. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Zaks Tal Zvi has traded 1 stock on record; the largest by dollars is TEVA.
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| S | Open-market sale | 1 | 17 | $593 |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 1 | 0 | 1 · $593 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| TEVA | Sell S | August 5, 2026 | August 10, 2026 | 5d | 17 | $35 | $593 | late | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| August 10, 2026 | Form 4 | 0001193125-26-341086 | 1 | published | EDGAR ↗ |
Other insiders at TEVA PHARMACEUTICAL INDUSTRIES LTD
- Savage Brian Interim Chief Legal Officer 5 rows
- Weiss Amir Chief Accounting Officer 4 rows
- Hughes Eric A See "Remarks" 3 rows
- Jover Placid See "Remarks" 3 rows
- MIGNONE ROBERTO Director 3 rows
- Kalif Eliyahu Sharon EVP, Chief Financial Officer 1 row
- Lippman Evan EVP, Business Development 1 row
- Satchi-Fainaro Ronit Director 1 row
- Shields Matthew EVP, Global Operations 1 row
Everyone on file, with contracts and lobbying under the company's name: TEVA PHARMACEUTICAL INDUSTRIES LTD.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 1 | 1 | August 10, 2026 | August 10, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.